Tekmira Pharmaceuticals Corp. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 67

Tekmira Pharmaceuticals Corp. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Tekmira Pharmaceuticals Corp. - Product Pipeline Review - H2 2011” provides data on the Tekmira Pharmaceuticals Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Tekmira Pharmaceuticals Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Tekmira Pharmaceuticals Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Tekmira Pharmaceuticals Corp. - Brief Tekmira Pharmaceuticals Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Tekmira Pharmaceuticals Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Tekmira Pharmaceuticals Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Tekmira Pharmaceuticals Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Tekmira Pharmaceuticals Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Tekmira Pharmaceuticals Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Tekmira Pharmaceuticals Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Tekmira Pharmaceuticals Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Tekmira Pharmaceuticals Corp. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Tekmira Pharmaceuticals Corp.; Tekmira Pharmaceuticals Corp. - Key Therapeutics; Tekmira Pharmaceuticals Corp. - Pipeline Overview and Promising Molecules; Tekmira Pharmaceuticals Corp. - News; Tekmira Pharmaceuticals Corp. - Latest Updates; Tekmira Pharmaceuticals Corp. - Pipeline; Tekmira Pharmaceuticals Corp. - Discontinued/Dormant Projects

List of Tables
List of Figures
Tekmira Pharmaceuticals Corp. Snapshot
Tekmira Pharmaceuticals Corp. Overview
Key Information
Key Facts
Tekmira Pharmaceuticals Corp. – Research and Development Overview
Key Therapeutic Areas
Tekmira Pharmaceuticals Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Tekmira Pharmaceuticals Corp. – Pipeline Products Glance
Tekmira Pharmaceuticals Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Tekmira Pharmaceuticals Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Tekmira Pharmaceuticals Corp. – Drug Profiles
PLK1 SNALP
Product Description
Mechanism of Action
R&D Progress
TKM-ApoB
Product Description
Mechanism of Action
R&D Progress
TKM-Ebola
Product Description
Mechanism of Action
R&D Progress
Tekmira Pharmaceuticals Corp. – Pipeline Analysis
Tekmira Pharmaceuticals Corp. – Pipeline Products by Therapeutic Class
Tekmira Pharmaceuticals Corp. - Pipeline Products By Target
Tekmira Pharmaceuticals Corp. – Pipeline Products by Molecule Type
Tekmira Pharmaceuticals Corp. – Recent Pipeline Updates
Tekmira Pharmaceuticals Corp. – Company Statement
Tekmira Pharmaceuticals Corp. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 28, 2009: Tekmira Pharmaceuticals Presents ApoB SNALP And PLK1 SNALP Data At Leading Scientific Conference
May 28, 2009: Tekmira Pharmaceuticals Presents ApoB SNALP Data At Leading Scientific Conference
Feb 24, 2010: Tekmira Presents ApoB SNALP Data At AsiaTIDES RNAi Scientific Conference
Feb 23, 2009: Tekmira Publishes PLK1 SNALP Anti-Tumor Efficacy Data
Dec 22, 2010: Tekmira Initiates TKM-PLK1 Phase I Human Clinical Trial
Apr 21, 2011: Tekmira And NCI Publish Promising Data Demonstrating Anti-Tumor Activity Of New Cancer Target
Apr 14, 2009: Tekmira Pharmaceuticals Files IND for ApoB SNALP
Sep 12, 2011: Tekmira And Collaborators Demonstrate Efficacy Of RNAi Against HCV
Jan 12, 2011: Tekmira's TKM-PLK1 Clinical Study Opens At TGen Clinical Research Services At Scottsdale Healthcare
Sep 10, 2010: Tekmira Delays Initiation Of Next TKM-ApoB Clinical Trial
Sep 10, 2010: Tekmira Initiates Development Of TKM-Ebola
Sep 10, 2010: Tekmira Plans To Expand Development Of TKM-PLK1 In Collaboration With NCI
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute
Sep 07, 2010: Tekmira Receives FDA Clearance To Initiate TKM-PLK1 Phase I Clinical Trial
May 07, 2009: Tekmira Pharmaceuticals Receives Clearance From FDA To Initiate ApoB SNALP Phase 1 Clinical Trial
Jan 07, 2010: Tekmira Pharmaceuticals Completes Phase 1 Clinical Trial Of ApoB SNALP
Aug 05, 2010: Tekmira Files PLK1 SNALP IND Application With FDA For Treatment Of Solid Tumor Cancers
Apr 04, 2011: Tekmira And Collaborators Present Data At American Association For Cancer Research Meeting On TKM-PLK1 and Oncology Product Candidate Targeting Kinase WEE1
Jul 02, 2009: Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
Financial Deals Landscape
Tekmira Pharmaceuticals Corp., Deals Summary
Tekmira Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Protiva Secures $3 Million In Venture Financing
Protiva Secures $5 Million In Venture Financing
Partnerships
Tekmira Pharmaceuticals Enters Into New Research Collaboration With Pfizer
Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Co-Development Agreement With Roche
Bristol-Myers Squibb Extends Research Agreement With Tekmira Pharmaceuticals
Tekmira Enters Into Research Agreement With Takeda Pharmaceuticals
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tekmira Pharmaceuticals
Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals
Protiva Biotherapeutics Enters Into Research Agreement With USAMRIID
Merger
Tekmira Pharmaceuticals Merges With Protiva Biotherapeutics
Licensing Agreements
Tekmira Enters Into Worldwide Licensing Agreement With Halo-Bio RNAi Therapeutics
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical
Tekmira Pharmaceutical Amends Licensing Agreement With Hana Biosciences
Tekmira Pharmaceuticals Enters Into Licensing Agreement With F. Hoffmann-La Roche
Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement
Merck Enters Into Licensing Agreement With Protiva Biotherapeutics
Hana Biosciences Enters Into Licensing Agreement With Inex Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Aradigm
Equity Offering
Tekmira Pharmaceuticals Completes Public Offering Of Units For $5.2 Million
Tekmira Completes Private Placement Of $5 Million With Alnylam
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Tekmira Pharmaceuticals Corp. – Pipeline by Therapy Area and Indication, H2 2011
Tekmira Pharmaceuticals Corp. – Pipeline by Stage of Development, H2 2011
Tekmira Pharmaceuticals Corp. – Monotherapy Products in Pipeline, H2 2011
Tekmira Pharmaceuticals Corp. - Phase I, H2 2011
Tekmira Pharmaceuticals Corp. - Pipeline By Therapeutic Class, H2 2011
Tekmira Pharmaceuticals Corp. - Pipeline By Target, H2 2011
Tekmira Pharmaceuticals Corp. – Pipeline By Molecule Type, H2 2011
Tekmira Pharmaceuticals Corp. – Recent Pipeline Updates, H2 2011
Tekmira Pharmaceuticals Corp., Subsidiaries
Tekmira Pharmaceuticals Corp., Deals Summary
Protiva Secures $3 Million In Venture Financing
Protiva Secures $5 Million In Venture Financing
Tekmira Pharmaceuticals Enters Into New Research Collaboration With Pfizer
Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Co-Development Agreement With Roche
Bristol-Myers Squibb Extends Research Agreement With Tekmira Pharmaceuticals
Tekmira Enters Into Research Agreement With Takeda Pharmaceuticals
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tekmira Pharmaceuticals
Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals
Protiva Biotherapeutics Enters Into Research Agreement With USAMRIID
Tekmira Pharmaceuticals Merges With Protiva Biotherapeutics
Tekmira Enters Into Worldwide Licensing Agreement With Halo-Bio RNAi Therapeutics
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical
Tekmira Pharmaceutical Amends Licensing Agreement With Hana Biosciences
Tekmira Pharmaceuticals Enters Into Licensing Agreement With F. Hoffmann-La Roche
Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement
Merck Enters Into Licensing Agreement With Protiva Biotherapeutics
Hana Biosciences Enters Into Licensing Agreement With Inex Pharmaceuticals
Tekmira Pharmaceuticals Enters Into Licensing Agreement With Aradigm
Tekmira Pharmaceuticals Completes Public Offering Of Units For $5.2 Million
Tekmira Completes Private Placement Of $5 Million With Alnylam

List of Figures
Tekmira Pharmaceuticals Corp. – Pipeline by Therapy Area and Indication, H2 2011
Tekmira Pharmaceuticals Corp. – Pipeline by Stage of Development, H2 2011
Tekmira Pharmaceuticals Corp. – Monotherapy Products in Pipeline, H2 2011
Tekmira Pharmaceuticals Corp. – Pipeline By Therapeutic Class, H2 2011
Tekmira Pharmaceuticals Corp. - Pipeline By Target, H2 2011
Tekmira Pharmaceuticals Corp. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• American Greetings Corp,(AM) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages